Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 35Genitourinary 15Gastrointestinal 9Other hematologic neoplasm 6Lymphoid 6Plasma cell 4Sarcoma 3Breast 3NET 2Endocrine 2Tumor-Agnostic 1Thoracic 1Gynecologic 1CNS 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1Neoplasms 1

Interventions

Dexamethasone 881Bortezomib 478Lenalidomide 467Cyclophosphamide 367Melphalan 275Calcium Dobesilate 264daratumumab 240pomalidomide 215carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 68Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 59Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Introns × Plasma cell × Clear all
NCT00004088 2019-07-02

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

City of Hope Medical Center

Phase 2 Completed
77 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00006244 2017-07-12

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 2 Completed
36 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00002556 2013-05-31

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
312 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡